A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)

Trial Profile

A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Jun 2017

At a glance

  • Drugs Brentuximab vedotin (Primary)
  • Indications T cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Jun 2017 According to a Seattle Genetics media release, based on the data from a phase III ALCANZA study and two phase 2 investigator-sponsored trials in patients with cutaneous T-cell lymphoma the company has submitted a supplemental Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA).
    • 24 Jun 2016 Status changed from not yet recruiting to recruiting.
    • 12 May 2016 Planned number of patients changed from 30 to 31.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top